Insider Buy: Veracyte
9:58AM ET 6/13/2022 MT NewswiresMarc Stapley, Director, Chief Executive Officer, on June 10, 2022, executed a purchase for 60,000 shares in Veracyte (VCYT) for $980,094. Following the...
Marc Stapley, Director, Chief Executive Officer, on June 10, 2022, executed a purchase for 60,000 shares in Veracyte (VCYT) for $980,094. Following the...
Veracyte (VCYT) said Friday that newly published data reinforce the clinical utility of the Decipher Prostate genomic classifier to treat men experiencing...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Address | 6000 Shoreline Court South San Francisco, California 94080 |
Phone | +1.650.243.6300 |
Number of Employees | 270 |
Recent SEC Filing | 06/16/2022![]() |
Chief Executive Officer & Director | Marc A. Stapley |
Chief Financial Officer | Rebecca Chambers |
Global Chief Scientific & Medical Officer | Giulia C. Kennedy |
Executive Medical Director | Richard T. Kloos |
Price Open | $19.41 |
Previous Close | $19.97 |
52 Week Range | $14.85 - 54.13 |
Market Capitalization | $1.4 B |
Shares Outstanding | 71.4 M |
Sector | Health Technology |
Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | N/A |
Earnings per Share | -$0.57 |
Beta vs. S&P 500 | N/A |
Revenue | $92.0 M |
Net Profit Margin | -19.22% |
Return on Equity | -4.52% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |